IL324467A - צורות פולימורפיות ופורמולציות של לריגליטזון - Google Patents

צורות פולימורפיות ופורמולציות של לריגליטזון

Info

Publication number
IL324467A
IL324467A IL324467A IL32446725A IL324467A IL 324467 A IL324467 A IL 324467A IL 324467 A IL324467 A IL 324467A IL 32446725 A IL32446725 A IL 32446725A IL 324467 A IL324467 A IL 324467A
Authority
IL
Israel
Prior art keywords
leriglitazone
crystalline
disease
degrees
syndrome
Prior art date
Application number
IL324467A
Other languages
English (en)
Inventor
Vidal Jos? Luis F?Bregas
P?REZ Montserrat MART?
Original Assignee
Minoryx Therapeutics S L
Vidal Jos? Luis F?Bregas
P?REZ Montserrat MART?
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L, Vidal Jos? Luis F?Bregas, P?REZ Montserrat MART? filed Critical Minoryx Therapeutics S L
Publication of IL324467A publication Critical patent/IL324467A/he

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL324467A 2023-05-09 2024-05-09 צורות פולימורפיות ופורמולציות של לריגליטזון IL324467A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23382428 2023-05-09
PCT/IB2024/054534 WO2024231881A2 (en) 2023-05-09 2024-05-09 Polymorphic forms and formulations of leriglitazone

Publications (1)

Publication Number Publication Date
IL324467A true IL324467A (he) 2026-01-01

Family

ID=86331222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL324467A IL324467A (he) 2023-05-09 2024-05-09 צורות פולימורפיות ופורמולציות של לריגליטזון

Country Status (5)

Country Link
EP (1) EP4709476A2 (he)
AU (1) AU2024268104A1 (he)
IL (1) IL324467A (he)
MX (1) MX2025013233A (he)
WO (1) WO2024231881A2 (he)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618847D0 (en) * 1986-08-01 1986-09-10 Smith Kline French Lab Pharmaceutical formulations
CA2106967C (en) * 1991-04-11 2003-12-09 Takashi Sohda Thiazolidinedione derivatives, production and use thereof
BR112014007366B1 (pt) * 2011-10-05 2020-09-15 Dupont Nutrition Usa, Inc Processo para fabricar uma composição estabilizadora compreendendo extrusão em duas etapas, composição estabilizadora de celulose microcristalina e produto alimentício comestível e suspensão industrial compreendendo a mesma
EP3125888B1 (en) * 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2016018860A1 (en) * 2014-07-29 2016-02-04 Fmc Corporation Improved colloidal stabilizer
EP3548026B1 (en) 2016-12-01 2021-01-20 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EA202092954A1 (ru) * 2018-06-06 2021-04-08 Минорикс Терапьютикс С.Л. Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
BR112020024917A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona
EP4142720A1 (en) * 2020-04-30 2023-03-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease

Also Published As

Publication number Publication date
EP4709476A2 (en) 2026-03-18
AU2024268104A1 (en) 2025-11-27
WO2024231881A2 (en) 2024-11-14
WO2024231881A3 (en) 2024-12-26
MX2025013233A (es) 2026-02-03

Similar Documents

Publication Publication Date Title
US7932273B2 (en) 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament
KR101684053B1 (ko) 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
CZ2015504A3 (cs) Krystalické formy obeticholové kyseliny
US20240417390A1 (en) Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same
TW420681B (en) Carbapenem-3-carboxylic acid ester derivatives
EP3613733A1 (en) Novel crystalline solid compound of 3-phenyl-4-propyl-1-(pyridin-2-yl)-1h-pyrazol-5-ol hydrochloride
TW201920163A (zh) (2s)‐2‐[[(z)‐[1‐(2‐胺基‐4‐噻唑基)‐2‐[[(3s)‐2,2‐二甲基‐4‐側氧基‐1‐(磺氧)‐3‐吖丁啶基]胺基]‐2‐氧亞乙基]胺基]氧基]‐3‐[4‐[亞胺基[(3r)‐3-哌啶基胺基]甲基]苯氧基]-丙酸之晶型
US20250382286A1 (en) Co-crystal of aficamten, and preparation method therefor and use thereof
US11124517B2 (en) Crystal form of Baricitinib and preparation method thereof
IL324467A (he) צורות פולימורפיות ופורמולציות של לריגליטזון
US11117868B2 (en) Edaravone salt
US11014888B2 (en) Crystalline form of alkynyl pyridine prolyl hydroxylase inhibitor and method for preparing same
US10479810B2 (en) Crystal form of tenofovir alafenamide salt, preparation method and use thereof
US20200199070A1 (en) Crystalline Eravacycline Bis-Hydrochloride
US20240059661A1 (en) Solid state forms of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
KR101741403B1 (ko) 안정한 결정형 보르테조밉
US20190263760A1 (en) Crystalline Forms of Lesinurad
IL312512A (he) אגוניסט לקולטן s1p1, מלחו, צורתו הגבישית, והרכב רוקחי
US10995083B2 (en) Cocrystal of 2-(6-methyl-pyridine-2-yl)-3-yl-[6-amide-quinoline-4-yl]-5,6-dihydro-4H-pyrrole[1,2-b]pyrazole, preparation method therefor, and pharmaceutical composition
US12180242B2 (en) Pharmaceutical crystal of contezolid acefosamil, preparation method therefor, and uses thereof
CN113603673B (zh) 一种盐酸度洛西汀的晶型、其制备方法及其应用
US20250026777A1 (en) Cocrystals of nicotinamide riboside salts, crystalline forms, methods of preparation, and applications thereof
US20220372006A1 (en) Solid state forms of pemafibrate
CN111747899B (zh) 嘧菌酯通道型溶剂化物、共晶及其制备方法
WO2023219106A1 (ja) 2-メチル-2-チアゾリンの塩